Our findings were In agreement with [15] and [38], who found that baricitinib at least has the same, or maybe better response rates than TNF inhibitors and explained this by the inhibitory effect of this new agent on the JAK/STAT pathway involved in the synthesis of many mediators responsible for the inflammatory process in RA, and proved by many studies [39, 40]. Here, SOAT1 is linked to rheumatoid arthritis.